HRP Anti-Kappa light chain antibody [EPR5367-8],Abcam,AB202549
What is this antibody validated in? HRP Anti-Kappa light chain antibody [EPR5367-8] (ab202549) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC-P), ELISA in Human samples. What is the molecular weight of Kappa light chain? Anti-Kappa light chain [EPR5367-8] HRP (ab202549) specifically detects a band for Kappa light chain (UniProt: P01834) at a molecular weight of 25kDa. Related products Antibody clone EPR5367-8 is also available pre-conjugated to a variety of labels for your convenience – Anti-Kappa light chain HRP [EPR5367-8] (ab202549). Other related products We have a range of other formats of antibody clone [EPR5367-8] also available for your convenience: ab124727 , HRP - ab202549, Alexa Fluor® 647 - ab202832 , Carrier free - ab232152 , Alexa Fluor® 488 - ab300547 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human, Human
Application
ELISA, WB, IHC-P
Conjugate
HRP
Platform ID
BAB465843168
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Constant region of immunoglobulin light chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268). See full target information IGKC
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.